Alexion Soars On Strong Q2 Soliris Sales
The biotech was able to raise its guidance for 2011 after it reported stronger than expected sales in the second quarter for its rare blood disease drug.
The biotech was able to raise its guidance for 2011 after it reported stronger than expected sales in the second quarter for its rare blood disease drug.